A US-based biopharmaceutical company specializing in RNA-targeted therapeutics collaborated with Elucidata to optimize its AAV-genome sequencing process, focusing on building custom pipelines to analyze in-house virion sequencing samples and ensure cassette quality.
The company faced challenges in building and managing AAV-genome sequencing analysis pipelines due to limited bioinformatics expertise, making it difficult to develop pipelines for contamination detection.
By offering advanced customization, precision, and quality control, Elucidata provided a solution that allowed the customer to independently manage and analyze in-house sequencing data with minimal external support.
Elucidata developed customized, scalable pipelines for DNA Contamination Detection, deployed on the customer’s AWS infrastructure. This solution improved plasmid purity estimation accuracy by 1,000-fold,automated the process end-to-end, and reduced pipeline development costs by 4X.
.svg)
.svg)
%201%20(1).svg)
.svg)
%201.svg){kind=icon}
.svg)
%20(1).svg)
